Zymeworks（NYSE:ZYME）股价上涨 5.4% - 这是怎么回事

Zymeworks Inc. (NYSE:ZYME - Get Free Report) shot up 5.4% on Thursday . The stock traded as high as $23.98 and last traded at $23.8270. 1,059,781 shares traded hands during trading, an increase of 60% from the average session volume of 663,603 shares. The stock had previously closed at $22.60.

Analyst Upgrades and Downgrades

• Zymeworks Offers Hope for More than Just Long-Term Investors

A number of analysts have issued reports on ZYME shares. Citigroup raised their price target on Zymeworks from $19.00 to $22.00 and gave the stock a "buy" rating in a research note on Monday, August 11th. B. Riley began coverage on shares of Zymeworks in a research report on Friday, October 10th. They issued a "buy" rating and a $30.00 target price on the stock. HC Wainwright boosted their target price on shares of Zymeworks from $26.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday. Stifel Nicolaus increased their price target on shares of Zymeworks from $30.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Leerink Partners set a $37.00 price target on shares of Zymeworks in a report on Monday. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Zymeworks has an average rating of "Moderate Buy" and a consensus price target of $29.88.

Get Our Latest Research Report on Zymeworks

Zymeworks Stock Up 5.4%

The firm's 50 day simple moving average is $17.87 and its 200-day simple moving average is $14.71. The company has a market capitalization of $1.78 billion, a PE ratio of -15.88 and a beta of 1.48.

Zymeworks (NYSE:ZYME - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business had revenue of $27.61 million for the quarter, compared to analyst estimates of $33.69 million. During the same quarter in the previous year, the business posted ($0.39) EPS. The business's quarterly revenue was up 72.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Zymeworks Inc. will post -1.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. EcoR1 Capital LLC increased its position in shares of Zymeworks by 33.1% during the second quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company's stock worth $288,278,000 after acquiring an additional 5,710,840 shares during the last quarter. Rubric Capital Management LP raised its position in shares of Zymeworks by 8.6% in the 2nd quarter. Rubric Capital Management LP now owns 4,710,551 shares of the company's stock valued at $59,117,000 after purchasing an additional 372,107 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Zymeworks by 184.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,879,945 shares of the company's stock valued at $46,210,000 after buying an additional 2,514,834 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Zymeworks by 53.5% during the 3rd quarter. Vestal Point Capital LP now owns 1,765,000 shares of the company's stock valued at $30,146,000 after buying an additional 615,000 shares during the last quarter. Finally, Deutsche Bank AG grew its position in shares of Zymeworks by 0.4% during the first quarter. Deutsche Bank AG now owns 1,552,612 shares of the company's stock worth $18,492,000 after buying an additional 5,840 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

Read More

• Five stocks we like better than Zymeworks
• Russell 2000 Index, How Investors Use it For Profitable Trading
• Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?
• Airline Stocks - Top Airline Stocks to Buy Now
• Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One
• The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
• Joby and Archer Forge a New Strategic Chapter in the UAE

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zymeworks Right Now?

Before you consider Zymeworks, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.

While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here